This results will be at poster session 2842 11 December from 10.

This results will be at poster session# 2842 11 December from 10.30 bis 19.00 clock clock presents local time in Hall E1 West, board 71 – III at the 48th Annual meeting of the American Society of Hematology Annual Meeting and Exposition in Orlando, Florida.

Treatment, theadditional positive results in HUMAX-CD20 CLL Phase I / II studyGenmab A / S announced today additional positive results in the HuMax-CD20 Phase I / II study for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia . Objective response rate was 50 percent was observed in patients with the highest dose patients treated. Nodular nodular partial remission by CT and one patient who qualified as nPR but were remaining lymphadenopathy was confirmed by CT. Continue reading